統合を超えて: 神経退行性疾患における病理的段階移行
Cécile Mathieu1, Rohit V Pappu2,3, J Paul Taylor4
1Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
まとめ
細胞の相変異は 組織にとって不可欠ですが その欠陥が神経変性疾患を 引き起こします 細胞の機能を回復する 治療の標的となるのです
科学分野:
- 細胞生物学
- 神経科学
- 生物化学
背景:
- 細胞組織は 細胞機能の根本的なプロセスである 段階的移行に依存しています
- これらの相変異の異常は,神経変性疾患の病原性における初期の出来事としてますます認識されています.
研究 の 目的:
- ステージトランジションの欠陥と神経変性との関連を検証する.
- 病理的相変の背後にあるメカニズムとその結果を解明する.
主な方法:
- 細胞組織と神経変性における相変化に関する既存の文献のレビュー.
- タンパク質とコンデンサートのレベルでの欠陥の分析
- ダイナミックアストとヘテロタイプのバッファリングのようなキーコンセプトの議論.
主要な成果:
- タンパク質と多重コンデンサートフェーズ移行の欠陥は神経変性に関連しています.
- 動的停止と異型バッファリングは 細胞機能障害とタンパク質の蓄積形成を説明します
- 病理的相変異は,プレオトロプ的細胞欠陥に寄与する.
結論:
- 神経退行性疾患の病因の鍵となるのは 異常な段階の移行を理解することです
- これらの洞察は新しい治療戦略の開発を導くことができます.
- 標的を絞った介入によって 細胞のホメオスタシスを回復することは 有望な治療法です
関連する概念動画
Amyloid Fibrils
11.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.4K
Amyloid Fibrils
6.1K
6.1K
Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Neural Regulation
42.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.6K
The Proteasome
1.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.4K


